SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Arcutis Begins Phase 3 Enrollment for ZORYVE Atopic Dermatitis Study

The INTEGUMENT-3 study will evaluate ZORYVE (roflumilast) cream 0.3% in moderate to severe atopic dermatitis.

ARQT

Related stories